Layer, Chiang, et al. Genome Biology
Oxford BioTherapeutics Licenses Antibody to Sanofi-Aventis for Cancer Drug Development
The agreement calls for Sanofi-Aventis to make to OBT an undisclosed upfront cash payment, with OBT eligible for future development, regulatory, and performance milestone payments and royalties on worldwide product sales.
New to GenomeWeb? Register here quickly.